Literature DB >> 18400984

Specific signals involved in the long-term maintenance of radiation-induced fibrogenic differentiation: a role for CCN2 and low concentration of TGF-beta1.

Valérie Haydont1, Bruce L Riser, Jocelyne Aigueperse, Marie-Catherine Vozenin-Brotons.   

Abstract

The fibrogenic differentiation of resident mesenchymal cells is a key parameter in the pathogenesis of radiation fibrosis and is triggered by the profibrotic growth factors transforming growth factor (TGF)-beta1 and CCN2. TGF-beta1 is considered the primary inducer of fibrogenic differentiation and is thought to control its long-term maintenance, whereas CCN2 is considered secondary effector of TGF-beta1. Yet, in long-term established fibrosis like that associated with delayed radiation enteropathy, in situ TGF-beta1 deposition is low, whereas CCN2 expression is high. To explore this apparent paradox, cell response to increasing doses of TGF-beta1 was investigated in cells modeling initiation and maintenance of fibrosis, i.e., normal and fibrosis-derived smooth muscle cells, respectively. Activation of cell-specific signaling pathways by low TGF-beta1 doses was demonstrated with a main activation of the Rho/ROCK pathway in fibrosis-derived cells, whereas the Smad pathway was mainly activated in normal cells. This leads to subsequent and cell-specific regulation of the CCN2 gene. These results suggested a specific profibrotic role of CCN2 in fibrosis-initiated cells. Furthermore, the modulation of CCN2 expression by itself and the combination of TGF-beta1 and CCN2 was investigated in fibrosis-derived cells. In fibrosis-initiated cells CCN2 triggered its autoinduction; furthermore, low concentration of TGF-beta1-potentiated CCN2 autoinduction. Our findings showed a differential requirement and action of TGF-beta1 in the fibrogenic response of normal vs. fibrosis-derived cells. This study defines a novel Rho/ROCK but Smad3-independent mode of TGF-beta signaling that may operate during the chronic stages of fibrosis and provides evidence of both specific and combinatorial roles of low TGF-beta1 dose and CCN2.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18400984     DOI: 10.1152/ajpcell.90626.2007

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  18 in total

Review 1.  Treatment of Radiation Injury.

Authors:  Sadanori Akita
Journal:  Adv Wound Care (New Rochelle)       Date:  2014-01-01       Impact factor: 4.730

Review 2.  Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease.

Authors:  Florian Rieder; Sean Kessler; Miquel Sans; Claudio Fiocchi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-08-09       Impact factor: 4.052

3.  Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice.

Authors:  Takahiro Kodama; Tetsuo Takehara; Hayato Hikita; Satoshi Shimizu; Minoru Shigekawa; Hinako Tsunematsu; Wei Li; Takuya Miyagi; Atsushi Hosui; Tomohide Tatsumi; Hisashi Ishida; Tatsuya Kanto; Naoki Hiramatsu; Satoshi Kubota; Masaharu Takigawa; Yoshito Tomimaru; Akira Tomokuni; Hiroaki Nagano; Yuichiro Doki; Masaki Mori; Norio Hayashi
Journal:  J Clin Invest       Date:  2011-07-11       Impact factor: 14.808

4.  EGCG blocks TGFβ1-induced CCN2 by suppressing JNK and p38 in buccal fibroblasts.

Authors:  Jenny Zwei-Chieng Chang; Wan-Hsien Yang; Yi-Ting Deng; Hsin-Ming Chen; Mark Yen-Ping Kuo
Journal:  Clin Oral Investig       Date:  2012-03-15       Impact factor: 3.573

5.  Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-β-induced fibrogenesis in human colonic myofibroblasts.

Authors:  Laura A Johnson; Eva S Rodansky; Andrew J Haak; Scott D Larsen; Richard R Neubig; Peter D R Higgins
Journal:  Inflamm Bowel Dis       Date:  2014-01       Impact factor: 5.325

6.  Advances in targeting the transforming growth factor β1 signaling pathway in lung cancer radiotherapy.

Authors:  Zhonghua Lu; Yiting Tang; Judong Luo; Shuyu Zhang; Xifa Zhou; Lei Fu
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

7.  Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues.

Authors:  Aadil A Khan; James T Paget; Martin McLaughlin; Joan N Kyula; Michelle J Wilkinson; Timothy Pencavel; David Mansfield; Victoria Roulstone; Rohit Seth; Martin Halle; Navita Somaiah; Jessica K R Boult; Simon P Robinson; Hardev S Pandha; Richard G Vile; Alan A Melcher; Paul A Harris; Kevin J Harrington
Journal:  Sci Transl Med       Date:  2018-01-24       Impact factor: 17.956

Review 8.  Targeting the TGF-beta1 pathway to prevent normal tissue injury after cancer therapy.

Authors:  Mitchell S Anscher
Journal:  Oncologist       Date:  2010

9.  Enhanced sensitivity to low dose irradiation of ApoE-/- mice mediated by early pro-inflammatory profile and delayed activation of the TGFβ1 cascade involved in fibrogenesis.

Authors:  Virginie Monceau; Lydia Meziani; Carine Strup-Perrot; Eric Morel; Magret Schmidt; Julia Haagen; Brigitte Escoubet; Wolfgang Dörr; Marie-Catherine Vozenin
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

10.  The TGF-β/Smad repressor TG-interacting factor 1 (TGIF1) plays a role in radiation-induced intestinal injury independently of a Smad signaling pathway.

Authors:  Mohammad Hneino; Agnes François; Valerie Buard; Georges Tarlet; Rym Abderrahmani; Karl Blirando; Pamela A Hoodless; Marc Benderitter; Fabien Milliat
Journal:  PLoS One       Date:  2012-05-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.